Forest Continues To Bank On Growth Of its Savella Medication for Fibromyalgia
This article was originally published in The Pink Sheet Daily
Executive Summary
With the only drug indicated solely for fibromyalgia, Forest expects Savella to help offset declining sales from its Lexapro antidepressant.
You may also be interested in...
Forest Should Conduct More Bystolic Studies For CHF Approval, Panel Says
An FDA panel decided that the agency should not approve Forest Laboratories' Bystolic (nebivolol) for chronic heart failure based on the current evidence, but suggested the drug could be approved for this added indication if the drug maker conducts a non-inferiority trial against other beta-blockers
Forest Should Conduct More Bystolic Studies For CHF Approval, Panel Says
An FDA panel decided that the agency should not approve Forest Laboratories' Bystolic (nebivolol) for chronic heart failure based on the current evidence, but suggested the drug could be approved for this added indication if the drug maker conducts a non-inferiority trial against other beta-blockers
Bystolic Advisory Committee: Trial Shortcomings Could Mean Tough Panel Review
Single pivotal trail for Forest's beta blocker may produce a skeptical audience on Jan. 11, when an FDA advisory committee evaluates the additional requested indication for chronic heart failure.